Postural tachycardia syndrome (POTS) and antiphospholipid syndrome (APS) : What do we know so far?

被引:3
作者
Noureldine, H. A. [1 ]
El Hasbani, G. [2 ]
Eldine, M. Nour [1 ]
Nour-Eldine, W. [3 ]
Taher, A. [4 ]
Uthman, I [2 ]
机构
[1] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Byblos, Lebanon
[2] Amer Univ Beirut, Dept Internal Med, Med Ctr, Beirut, Lebanon
[3] Hamad Bin Khalifa Univ, Qatar Fdn, Neurol Disorders Res Ctr, Qatar Biomed Res Inst, Doha, Qatar
[4] Amer Univ Beirut, Dept Internal Med, Div Hematol & Med Oncol, Med Ctr, Beirut, Lebanon
关键词
Antiphospholipid syndrome; Postural orthostatic tachycardia    syndrome; Autonomic dysfunction; Antiphospholipid antibodies; Cytokines; Anticoagulation; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTONOMIC DYSFUNCTION; HUGHES-SYNDROME; DERMATOLOGICAL MANIFESTATIONS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; ANGIOTENSIN-II; C1Q RECEPTORS; NEUROPATHY;
D O I
10.1016/j.neurol.2021.10.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As part of the non-criteria clinical manifestations, postural orthostatic tachycardia syndrome (POTS), a multisystem autonomic dysfunction, can co-exist with antiphospholipid syndrome (APS). Several pieces of evidence hint on the autoimmune basis of POTS, and its possible association with several autoimmune diseases, including APS. Indeed, the evidence exists in the etiologies, symptomatology, and treatment options. Although infections, viral ones in particular, stress, and pregnancy are etiologies to both POTS and APS, the exact pathophysiological connection is still to be studied taking into consideration the activity of cytokines in both diseases. Nevertheless, certain immunomodulatory treatments used for the catastrophic or obstetrical forms of APS, such as intravenous immunoglobulins (IVIG) and steroids, have been also used for the treatment of POTS resistant to classical treatments. Therefore, our review aims to highlight the association between POTS and APS, shedding light on the common etiologies explaining the pathophysiology of the two disorders, the diagnostic approach to POTS as a possible clinical criterion of APS, and the treatment of APS in the context of treating POTS. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 37 条
  • [21] Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume
    Stewart, JM
    Glover, JL
    Medow, MS
    CLINICAL SCIENCE, 2006, 110 (02) : 255 - 263
  • [22] Potential therapeutic agents against COVID-19: What we know so far
    Lu, Chih-Chia
    Chen, Mei-Yu
    Lee, Wan-Shin
    Chang, Yuh-Lih
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (06) : 534 - 536
  • [23] What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?
    Omar Latino, Jose
    Udry, Sebastian
    Peres Wingeyer, Silvia
    Fernandez Romero, Diego
    Micone, Paula
    de Larranaga, Gabriela
    IMMUNOLOGIC RESEARCH, 2018, 66 (05) : 577 - 583
  • [25] Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: What advice should we be giving?
    Lakasing, L
    Khamashta, M
    JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2001, 27 (01) : 7 - +
  • [26] On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
    Santocki, Michal
    Kolaczkowska, Elzbieta
    CELLS, 2020, 9 (09) : 1 - 25
  • [27] Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation?
    Derksen, RHWM
    de Groot, PG
    JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) : 255 - 259
  • [28] B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover
    Colucci, Manuela
    Oniszczuk, Julie
    Vivarelli, Marina
    Audard, Vincent
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes - What We Know so Far and the Missing Links
    Groener, Jan Benedikt
    Oikonomou, Dimitrios
    Cheko, Ruan
    Render, Zoltan
    Zemva, Johanna
    Kihm, Lars
    Muckenthaler, Martina
    Peters, Verena
    Fleming, Thomas
    Kopf, Stefan
    Nawroth, Peter P.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2019, 127 (08) : 497 - 504
  • [30] Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far
    Shalaby, Youssef M.
    Al Aidaros, Anas
    Valappil, Anjana
    Ali, Bassam R.
    Akawi, Nadia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9